Systems, methods, and techniques disclosed and contemplated herein relate to processing high level radioactive waste (HLW). Exemplary techniques are applicable to various fuel types, such as metal/chloride salt HLW streams from pyroprocessing of sodium bonded metallic fast reactor fuel; metal and halide salt HLW from molten salt reactors; and SiC/pyrolytic carbon from mechanically breached TRISO (tri -structural isotropic particle fuel) kernels with oxide fission products (FPs) from reprocessing. Exemplary waste forms are cermets.
2.
METHODS AND SYSTEMS FOR DETERMINING GROUP MOTION PATTERNS
An embodiment provides a lightweight approach to real-time crowd pattern identification, and motion pattern determination using processes of existing video compression standards. An embodiment obtains a plurality of motion vectors, each motion vector indicating movement of a macroblock from a first frame of video data to a second frame of video data. Based on the plurality of motion vectors, a polygonal contour surrounding a subset of motion vectors from the plurality of motion vectors is determined, wherein the polygonal contour represents at least part of the group. A motion pattern of the group is identified based on the determined polygonal contour and the subset of motion vectors from the plurality of motion vectors.
H04N 19/176 - Methods or arrangements for coding, decoding, compressing or decompressing digital video signals using adaptive coding characterised by the coding unit, i.e. the structural portion or semantic portion of the video signal being the object or the subject of the adaptive coding the unit being an image region, e.g. an object the region being a block, e.g. a macroblock
Methods and systems for determining a disease state by obtaining a first plurality of nucleic acid sequences for genomic DNA from a sample from the gut of a subject. Determine, from the nucleic acid sequences a first plurality of genomic abundance values for a first plurality of gut bacteria and a second plurality of genomic abundance values for a second plurality of at least 20 species of gut bacteria. Apply a model to at least the first plurality of genomic abundance values and the second plurality of genomic abundance values, or one or more combinations thereof, thereby determining the disease state of the subject as an output of the model.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
A spiking neural network is provided, wherein each neuron of the spiking neural network includes a RC or RLC circuit formed of passive elements. The RC or RLC circuit provides a corresponding spiking function. In some cases, a portion of each neuron of the spiking neural network is implemented in a digital processor and further includes a digital to analog converter between the portion implemented in the digital processor and the RC or RLC circuit. In some cases, the spiking neural network is implemented as a fully analog neural network.
Disclosed is a concise, inexpensive and scalable method for preparing elastomers filled with conductive 2D nanoparticles. The method comprises independently filling elastomer polymer precursors and/or corresponding elastomer polymer curing agents or their precursors with conductive 2D nanoparticles by shear exfoliation of a layered material, followed by mixing the two components and curing to form the elastomer. Such filled elastomers have utility in preparing various types of sensors which are useful in a variety of practical applications and devices.
Disclosed herein are compounds useful for treating obstructive lung diseases. The compounds are TAS2Rs agonists and may further be used to treat disorders and conditions implicated by TAS2R. In some instances the disclosed compounds can be used to treat asthma.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
8.
CARDIAC ULTRASONIC FINGERPRINTING: AN APPROACH FOR HIGH-THROUGHPUT MYOCARDIAL FEATURE PHENOTYPING
A system for identifying cardiac injury is provided herein. The system includes at least one computing device and at least one application executable on the at least one computing device. The application causes the computing device to extract a plurality of radiomic features from an ultrasound scan associated with a patient, determine one or more myocardial characteristics by applying the extracted plurality of radiomic features to one or more phenotyping models, and identify a cardiac injury associated with the patient based at least in part on the one or more myocardial characteristics and matching the extracted plurality of radiomic features to a patient cluster.
Described are sulfinate salts and methods of using the same in synthesis. The sulfinate salt may be a salt of formula (I): wherein: a is 1 or 2; X+ais a cation having a +a charge; R121-41-41-4alkyl, F, or Cl; and R21-41-422; with the proviso that at least one of R1and R2 is not hydrogen.
C07C 303/02 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
C07C 303/22 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids by reactions not involving the formation of sulfo or halosulfonyl groups
C07D 307/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
A composition is provided. The composition comprises a polyol part. The polyol part comprises a catalyst, a defoamer, and modified nanoparticles. The catalyst comprises at least one of a base catalyst, a metal catalyst, a quaternary ammonium catalyst, a phosphorus-based catalyst, or any combination thereof. The composition is an elastomeric polyurethane sealer.
A61K 6/831 - Preparations for artificial teeth, for filling teeth or for capping teeth comprising non-metallic elements or compounds thereof, e.g. carbon
11.
piRNA-BASED CONSTRUCTS FOR REGULATING GENE EXPRESSION AND METHODS OF USE THEREOF
This disclosure is based, in part, on the unexpected discovery that a piRNA-based construct is able to silence genes that are essential for transmission and/or infection of pathogens. The disclosed constructs and methods of use thereof capitalize on the role piRNAs play in transcriptional silencing and general immunity and enable development of transgenic approaches to inhibit transmission of human and crop diseases.
The present invention includes recombinant AAV vectors comprising an inducible transcriptional activator which is operably linked to a muscle-specific promoter, wherein the AAV vector further comprises a capsid gene specific for muscle tissue. The invention further includes methods of producing and using said recombinant AAV vectors to introduce transgenes into target cells and treat diseases in subjects in need thereof.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
13.
COMPOSITIONS AND METHODS FOR THE ISOLATION AND PURIFICATION OF ANTI-FUNGAL PROTEIN FROM EPICHLOE FESTUCAE AND USE THEREOF FOR REDUCING SYMPTOMS OF DOLLAR SPOT DISEASE IN TARGETED PLANT SPECIES
Foundry casting elements and methods of forming the same, the methods including: forming an aqueous slurry including an inorganic binder precursor, shaping the slurry using a pattern, curing the shaped slurry using a low temperature solidification process to form a casting element, and removing the pattern from the casting element.
B22C 1/12 - Compositions of refractory mould or core materialsGrain structures thereofChemical or physical features in the formation or manufacture of moulds characterised by additives for special purposes, e.g. indicators, breakdown additives for manufacturing permanent moulds or cores
B22C 1/14 - Compositions of refractory mould or core materialsGrain structures thereofChemical or physical features in the formation or manufacture of moulds characterised by additives for special purposes, e.g. indicators, breakdown additives for separating the pattern from the mould
B22C 1/16 - Compositions of refractory mould or core materialsGrain structures thereofChemical or physical features in the formation or manufacture of moulds characterised by the use of binding agentsMixtures of binding agents
B22C 1/18 - Compositions of refractory mould or core materialsGrain structures thereofChemical or physical features in the formation or manufacture of moulds characterised by the use of binding agentsMixtures of binding agents of inorganic agents
B22C 3/00 - Selection of compositions for coating the surfaces of moulds, cores, or patterns
B82B 1/00 - Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
B82B 3/00 - Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
16.
ANTIMICROBIAL COMPOSITION FOR INHIBITING MICROBIAL ORGANISMS IN ALLOGRAFT AND THE METHOD THEREOF
Methods for producing allograft tissue by applying an antimicrobial solution to allograft tissue. The antimicrobial solution exhibits antimicrobial activity to make allograft resistant to microbial organisms, such as bacterium. Surface-modified tissue grafts prepared by these methods are also disclosed.
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
The present disclosure relates to a biomaterial matrix having a live bacteria impregnated hydrogel, using the biomaterial matrix to treat epidermal inflammation of an animal, and wearable electronic devices having the biomaterial matrix installed thereon.
Compositions and methods for the rapid and efficient production of transgenic soybean expressing heterologous proteins or RNAs of interest in seed, pod and root plastids are disclosed.
C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
A01H 6/46 - Gramineae or Poaceae, e.g. ryegrass, rice, wheat or maize
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
21.
METHODS OF DIAGNOSING B CELL MALIGNANCIES, DETECTING B CELL MALIGNANCY RELAPSE, AND TREATING THEREOF
Embodiments described here are directed to novel methods for detecting commensal bacteria-specific antibodies, such as commensal bacteria-specific immunoglobulin antibodies, in a blood sample or tissue fluid from a subject suspected of or suffering from a B cell malignancy, where the methods are for early detection or diagnosis of B cell malignancies and for early detection of relapse or recurrence of a B cell malignancy in remission patients previously diagnosed as suffering from a B cell malignancy. Also, described are embodiments directed to apparatuses for use with the novel methods described here. Methods of treating a subject suspected of or suffering from a B cell malignancy or a relapse or a recurrence of a B cell malignancy that can be used in combination with or without the methods of detecting commensal bacteria-specific antibodies and/or standard of care treatment are also provided here.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
The disclosure provides compound of formula (I): or a salt thereof, wherein R'-R10, W, X, Y, and Z have any of the values described in the specification, as well as compositions comprising such compounds or salts, methods of making such compounds and salts, and methods of using such compounds and salts, e.g., as inhibitors of bacterial RNA polymerase and as antibacterial agents.
A method, including: establishing an electric field (210) in an electrospray deposition device (100B) and within the electric field emitting a spray of a medium (114) comprising payload materials (116A) from an emitter (104) toward a conductive target (132) disposed on an insulated conductive body (200); disposing charged payload materials (116BE) on the insulated conductive body; and establishing field lines (130BE) in the electric field between the emitter and the charged payload materials on the insulated conductive body to stabilize the electric field and between the emitter and the target to carry the spray of the medium to the target.
The invention provides compounds of formula (I):
The invention provides compounds of formula (I):
The invention provides compounds of formula (I):
wherein R1-R3, n, and W have any of the values defined in the specification, and salts thereof. The compounds have good solubility and are useful for treating bacterial infections.
C07C 235/88 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having the nitrogen atom of at least one of the carboxamide groups further acylated
C07D 277/64 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
26.
COMPOSITIONS AND METHODS FOR TARGETING INSULIN RECEPTOR ISOFORM A (IR-A)
Described herein are compounds, compositions, and methods for selectively targeting insulin receptor isoform A (IR-A). In some embodiments, the compounds, compositions, and methods comprise an antisense oligonucleotide (ASO) targeted to IR-A for treating or preventing diseases and conditions characterized by elevated IR-A expression. In some embodiments, the compounds, compositions, and methods selectively reduce an expression level of IR-A. In some embodiments, the ASO comprises a modified oligonucleotide comprising at least one modified internucleoside linkage and at least one modified sugar moiety. In some embodiments, the disease or condition comprises cancer, diabetes, or a combination thereof. Also described herein are compounds, compositions, and methods for inhibiting cancer cell growth or proliferation.
An anchorage system for prestressing a non-metallic (e.g., FRP) tendon against a support member may include a dead-end assembly and a live-end assembly configured to be placed on opposite sides of the support member, each assembly having a support sleeve affixed to a support plate. The anchorage system may also include a tensioning rod coupled to an end of the support sleeve of the live-end assembly that is remote from the respective support plate, and a removable support box extending around the support sleeve of the live-end assembly, the tensioning rod extending through an opening defined in the removable support box, the support box configured to be an abutment structure against which a jack may be placed. The anchorage system may also include one or more slotted shim plates interposed between the support plate of the live-end assembly and a first confronting surface of the support member.
Techniques for determining a condition of a subject includes recording auditory brain stem (ABS) electrical signal data in a subject in response to an auditory signal delivered to the subject. First data is determined, wherein the first data indicates a temporal latency for each vertex in a set of one or more vertices in the ABS electrical signal or a property of one or more micropeaks in a portion of the electrical signal away from the vertices, or some combination. Each vertex indicates a response from a different anatomical location from the cochlea to the auditory cortex of the subject. A condition of the subject is determined based on a distance of the temporal latency determined for each vertex, or the property of the micropeaks, or some combination, from a predetermined set of values for temporal latency or property of micropeaks in a population of control individuals.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
30.
COMPOSITIONS AND METHODS COMPRISING MODIFIED CHIMERIC ANTIGEN RECEPTOR (CAR) MACROPHAGES
Described herein are compositions and methods for treating various indications in a subject including, but not limited to, atherosclerosis, cardiovascular diseases, inflammation, chronic inflammatory diseases, wounds, and spinal cord injuries. In some embodiments, the compositions and methods comprise a modified macrophage or monocyte comprising surface-expressed CD47-targeted chimeric antigen receptor (CAR) proteins and lipid-based particles conjugated to a surface of the modified macrophage or monocyte, wherein the lipid-based particles comprise a β-cyclodextrin (β-CD). In some embodiments, the lipid-based particles comprise lipid nanoparticles (LNPs).
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
31.
OXAMATE DERIVATIVES AND PRODRUGS TO PREVENT CAOX STONE FORMATION
This patent document discloses novel oxamaies that can act as potent inhibitors of calcium oxalate (CaOx) crystallization and new macrocyclic prodrugs that will offer improved lipophilicity, small size, lower polar surface area, and greatly reduced solvent accessible surface area, all properties known to impart better oral bioavailability. Also disclosed herein are methods of treating diseases associated with abnormal levels of calcium oxalate and its crystallization.
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
32.
SYSTEMS AND METHODS FOR TRAINING PHYSICS-INFORMED NEURAL NETWORK SURROGATE MODELS TO MODEL PHYSICAL PROBLEMS USING THE FINITE ELEMENT METHOD
Systems and methods for training physics-informed neural network (PINN) surrogate models to model physical problems are provided. The method may comprise coupling, using a processor, one or more convolutional neural networks (CNNs) with a finite element method (FEM). The coupling may comprise calculating, for a finite element mesh comprising a plurality of finite elements, an internal force vector, P, a force vector, F, and a tangent stiffness matrix, KT, using the FEM. Each finite element may comprise one or more finite element nodes. The coupling may further comprise applying a CNN to the finite element mesh to obtain a solution to a physical problem. The CNN may be trained on a loss function, and the loss function may incorporate the internal force vector, P, and the force vector, F.
Synthesis of multi-cation oxide utilizing recycled carbonate-containing material. Also provided is a method of capturing carbon dioxide and releasing it as needed.
Using a novel dependence on plasmid-mediated expression (DOPE) technology, conditional depletion of GrgA, a Chlamydia-specific protein, has been demonstrated to result in greatly reduced reticulate body (RB) proliferation rate and near complete lack of elementary body (EB) formation, thus disrupting the normal chlamydial developmental cycle. This conditional GrgA-deficient Chlamydia allows study of chlamydial growth and developmental regulation and can be used as the basis of an attenuated, maturation-defective but immunogenic bacteria for use as an avirulent vaccine against Chlamydia.
The present disclosure provides substituted imidazo[1,5-a]pyridine N-heterocyclic carbene (NHC) ligands, catalyst complexes thereof, and methods using same. The present disclosure further provides synthetic methods of preparing N-heterocyclic carbene ligands and catalyst complexes thereof.
The invention provides inhibitors of interferon regulatory factor 5 (IRF5) nuclear localization and methods of using the inhibitors to treat autoimmune diseases such as systemic lupus erythematosus (SLE).
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Research Foundation of the City University of New York (USA)
Rutgers, The State University of New Jersey (USA)
Universidad Nacional De San Martin (Argentina)
UNIVERSIDAD NACIONAL DE SAN MARTIN (Argentina)
Inventor
Choi, Junyong
Kim, Hee-Sook
Erben, Esteban
Hossain, Zakir
Mukherjee, Aditi
Sharma, Diya
Abstract
A composition of matter having a general structure of:
A composition of matter having a general structure of:
A composition of matter having a general structure of:
The composition selectively inhbits Replacement Proteins A1 (RPA1) of Trypanosoma brucei.
The invention provides methods and compositions that are useful for treating allergic diseases, bacterial infections, fungal infections, viral infections, mastocytosis, mast cell-mediated inflammation and parasite infections (e.g., helminth infections).
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/542 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Compositions comprising biologically active synthetic nanoparticle constructs and methods of use thereof to modify mitochondrial gene expression including transcriptional repression and transcriptional activation.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
40.
Nuclease-Independent Targeted Gene Editing Platform and Uses Thereof
The Board of Trustees of the Leland Stanford Junior University (USA)
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (USA)
YALE UNIVERSITY (USA)
Inventor
Pelechano Garcia, Vicente Jose
Barrett, Donal
Steinmetz, Lars M.
Javanmard, Mehdi
Tayyab, Muhammad
Scharfe, Curt
Griffin, Peter B.
Abstract
Provided herein is a method for detecting a target nucleic acid in a sample. In some embodiments, the method may comprise: (a) amplifying the target nucleic acid isothermally in the presence of one or more compaction oligonucleotides to produce a product that comprises condensed amplification products; (b) flowing the product through a microfluidic channel; and (c) detecting a change in impedance as the condensed amplification products pass through the microfluidic channel. A microfluidic system and kit for preforming the method are also provided.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
42.
COMPOSITIONS AND METHODS FOR CONTROLLING DROSOPHILA FLIES
A01N 37/02 - Saturated carboxylic acids or thio-analogues thereofDerivatives thereof
A01N 25/02 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
A01N 37/06 - Unsaturated carboxylic acids or thio-analogues thereofDerivatives thereof
Methods of expanding a population of immune cells, such as natural killer cells or CAR-modified natural killer cells, using exosomes, and methods of producing the exosomes from a population of 721.221 cells transduced or transfected with a membrane-bound IL-21 (mIL-21) or a population of 721.22 cells transduced or transfected with a mIL-21 and B7-H6. Methods of treating a cancer or an infectious or immune disease, wherein immune cells expanded using the exosomes are administered to a subject with the cancer or the infectious or immune disease are also provided.
Disclosed herein are embodiments of compounds that exhibit Crk-like protein inhibition. The compound embodiments can be used to suppress or prevent tumor cell growth and/or to inhibit a Crk-mediated signaling pathway. Methods of making and using the compound embodiments are disclosed herein.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/39 - Heterocyclic compounds having sulfur as a ring hetero atom having oxygen atoms in the same ring
A61K 31/665 - Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
A robot arm having a series of rigid links including a first rigid link and a final rigid link, the links being operatively controlled via tendon-driven joints, each tendon-driven joint comprising a motorized spool configured to rotate in either of two directions and operatively coupled, via a cable assembly having an elastic portion, to a pulley configured to move a respective rigid link thereby. A controller adapts robot arm motion in response to position and force sensing signals. A tendon-driven joint may be implemented via one motor controlling the tension of two cables acting in opposing directions and coupled between respective ones of a pair of common-driven spools and a pair of pulleys.
Nanoparticle compositions and methods inhibiting amyloid beta (Aβ) fibrilization in a subject in need thereof using nanoparticles to target fibril β-amyloid (fAβ)-specific scavenger receptors. Also provided is a method of using nanoparticle compositions to treat Alzheimer's disease (AD) and similar amyloidopathies.
Methods and systems for predicting a subject's response to a therapy by obtaining a first plurality of nucleic acid sequences for genomic DNA from a sample from the gut of a subject. Determine, from the nucleic acid sequences, a plurality of genomic abundance values for a plurality of gut bacteria. Apply a model to the plurality of genomic abundance values, thereby obtaining the prediction of a subject's response to a therapy as an output of the model.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
A method for forming a scaffold for use in fabricating a soft tissue implant, comprising: receiving, by a processor, soft tissue data corresponding to dimensions for a soft tissue, and a first and second weighting factor selected based on the dimensions of the soft tissue; transforming, by the processor, the soft tissue data, based on the first and second weighting factors, into a plurality of pin coordinates in a multi-dimensional space defining a shape of the scaffold for use in fabricating the soft tissue implant; and providing, by the processor, instructions to form the scaffold using weaving operations based on the pin coordinates.
The disclosure provides, in various embodiments, antibodies and antigen binding fragments thereof, and polypeptides that bind tumor necrosis factor-alpha (TNF-α). The disclosure also provides, in various embodiments, polynucleotides encoding antibodies and antigen binding fragments thereof, and polypeptides; vectors and host cells suitable for expressing the antibodies and antigen binding fragments thereof, and polypeptides; and methods for treating TNF-α-associated diseases or conditions.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
53.
COMPUTER-IMPLEMENTED METHODS FOR QUANTUM MECHANICAL BINDING AFFINITY SCORING
RUTGERS, THE STATES UNIVERSITY OF NEW JERSEY (USA)
Inventor
Pavanello, Michele
Genova, Alessandro
Martinez Bernal, Jessica
Abstract
Provided herein are computer-implemented methods for scoring a binding affinity between molecular subsystems. The methods include representing an interaction structure of the molecular subsystems, calculating the molecular interactions between the molecular subsystems, and generating an interaction energy score between the molecular subsystems.
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
A reared colony of larval superworms (Zophobas morio) experienced the swift and unexplained death of about 90% of its population. From dead larvae, a high-abundance virus was isolated and identified as a novel densovirus, Zophobas morio black wasting virus (ZmBWV), by means of cryo-electron microscopy. Strains of this virus were sequenced and an engineered vaccine virus sequence was developed. The black wasting disease was replicated in larvae by inoculation with pathogenic strains of ZmBWV. Larvae were inoculated with a non-pathogenic strain as prophylaxis and later challenged by inoculation with a pathogenic strain. The larvae that received a non-pathogenic strain were protected from later disease and death but the larvae that received a saline solution were not. The invention provides methods and vaccine products to inhibit morbidity and mortality of ZmBWWV in darkling beetle larvae.
A composition tor use in treating a dental implant. Tire composition comprises a porous biodegradable polymer scaffold and a dicalciurn phosphate dihydrate (DCPD) coating within pores of the scaffold.
Embodiments operate a plurality of autonomous agents in a real-world environment. In an embodiment, each of the plurality of autonomous agents determines if a communication condition is above or below a threshold. Responsive to determining the communication condition is above the threshold, each agent determines a real-world action in the environment based on a respective indication of properties of the environment and a coordination communication. Responsive to determining the communication condition is below the threshold, each agent determines a real-world action in the environment based on the respective indication of properties of the environment. In turn, each agent performs its determined real-world action in the environment.
This disclosure provides compositions and methods for eliciting a T-cell mediated response to a pathogen or a tumor cell. Also provided are T-cell vaccines, T-cell adjuvants, and methods for performing T-cell diagnostics.
This disclosure provides recombinase enzymes that enable isothermal amplification of DNA or RNA. Also provided are consumer-friendly diagnostic devices in which the isothermal amplification occurs and a sample is analyzed. In particular, the recombinase enzymes and described diagnostic devices are used to detect inter alia, infectious diseases or non-infectious disease.
A device for treating neonatal intraventricular hemorrhage or brain injury comprises at least one laser configured to emit laser energy directed to a fontanelle or unfused suture of a neonatal cranium. The device includes a control unit electronically coupled to the laser or array of lasers. The control unit is configured to determine at least one laser parameter, such as a wavelength, an irradiance intensity, a voltage intensity, a power output, a focus angle, a focus distance, a duration of emission, a mode of emission, and a pulse frequency. A method of treatment using the device is also disclosed.
The present disclosure relates, in part, to a method for preparing a carbon nanomaterial from a plastic material. In certain embodiments, the method comprises nonsolvent induced phase separation of the plastic material to provide plastic nanoparticles. In certain embodiments, the method comprises hydrothermal conversion of the plastic nanoparticles to carbon nanomaterials. In certain embodiments, the plastic material is derived from waste material. In certain embodiments, the plastic material is polypropylene (PP). In certain embodiments, the carbon nanomaterial is carbon dots (CDs). In another aspect, the disclosure provides a method for altering the properties of CDs by post-processing to afford graphitic materials.
The invention provides methods of inhibiting a bacterial RNA polymerase and methods of treating a bacterial infection with salts of formula Ia, Ib, Ic, or Id:
The invention provides methods of inhibiting a bacterial RNA polymerase and methods of treating a bacterial infection with salts of formula Ia, Ib, Ic, or Id:
The invention provides methods of inhibiting a bacterial RNA polymerase and methods of treating a bacterial infection with salts of formula Ia, Ib, Ic, or Id:
wherein variables are as described in the specification.
The Board of Regents of The University of Texas System (USA)
Inventor
Lynch-Branzoi, Jennifer K.
Ashraf, Ali
Rahman, Ashiqur
Islam, Nazmul
Abstract
Sensors employing elastomers enhanced with electrically conductive 2D nanoparticles are provided. The nanoparticles are formed by applying shear to layered materials present in elastomer precursors (e.g., elastomeric monomer(s) and/or curing agent(s)). Subsequent exfoliation of the layers occurs directly within the precursor and/or curing agent. The cured elastomer nanocomposites can be employed for electrochemical sensing, flexible touchpads, pressure sensors, and wireless sensors, amongst other applications.
B01F 23/53 - Mixing liquids with solids using driven stirrers
B01F 23/70 - Pre-treatment of the materials to be mixed
B01F 27/232 - Mixers with rotary stirring devices in fixed receptaclesKneaders characterised by the orientation or disposition of the rotor axis with two or more rotation axes
B01F 101/00 - Mixing characterised by the nature of the mixed materials or by the application field
C08J 3/22 - Compounding polymers with additives, e.g. colouring using masterbatch techniques
G01L 1/14 - Measuring force or stress, in general by measuring variations in capacitance or inductance of electrical elements, e.g. by measuring variations of frequency of electrical oscillators
G01L 1/22 - Measuring force or stress, in general by measuring variations in ohmic resistance of solid materials or of electrically-conductive fluidsMeasuring force or stress, in general by making use of electrokinetic cells, i.e. liquid-containing cells wherein an electrical potential is produced or varied upon the application of stress using resistance strain gauges
G01N 27/30 - Electrodes, e.g. test electrodesHalf-cells
G06F 3/0354 - Pointing devices displaced or positioned by the userAccessories therefor with detection of 2D relative movements between the device, or an operating part thereof, and a plane or surface, e.g. 2D mice, trackballs, pens or pucks
63.
METHODS OF DIAGNOSING B CELL MALIGNANCIES, DETECTING B CELL MALIGNANCY RELAPSE, AND TREATING THEREOF
Embodiments described here are directed to novel methods for detecting commensal bacteria-specific antibodies, such as commensal bacteria-specific immunoglobulin antibodies, in a blood sample or tissue fluid from a subject suspected of or suffering from a B cell malignancy, where the methods are for early detection or diagnosis of B cell malignancies and for early detection of relapse or recurrence of a B cell malignancy in remission patients previously diagnosed as suffering from a B cell malignancy. Also, described are embodiments directed to apparatuses for use with the novel methods described here. Methods of treating a subject suspected of or suffering from a B cell malignancy or a relapse or a recurrence of a B cell malignancy that can be used in combination with or without the methods of detecting commensal bacteria-specific antibodies and/or standard of care treatment are also provided here.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
C12M 1/40 - Apparatus specially designed for the use of free, immobilised, or carrier-bound enzymes, e.g. apparatus containing a fluidised bed of immobilised enzymes
A tiltable near-vertical bifacial (TNVBF) solar panel assembly comprising one or more BF solar panels configured to be positioned in a first (AM) tilt position to improve energy conversion of morning sunlight incident upon a first side of the one or more BF solar panels, and to be positioned in a second (PM) tilt position to improve energy conversion of afternoon sunlight incident upon a second side of the one or more BF solar panels.
The present disclosure relates to a new modular approach for the generation of genetically modified cells, particularly immune cells and iPSCs, enabling the simultaneous precise editing of defined nucleic acid targets (knock-out) and the introduction of an exogenous sequence of choice at a desired locus (knock-in) using a common Cas9 element.
Techniques for determining control in digital interactions include recording a time series of digital sub-second sensor data for each of multiple subjects. A mean and a variance are determined for a feature of micropeaks in the time series of digital sub-second sensor data. An autonomy and control score are determined for each subject of the multiple subjects based at least in part on the mean and variance of the feature. Sometimes a micropeak occurrence feature of the micropeaks is transformed to a binary time series, and the autonomy and control score is also based at least in part on entropy rate of the binary time series or transfer entropy between two binary time series, or some combination.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G06V 40/20 - Movements or behaviour, e.g. gesture recognition
G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
68.
COMPOSITIONS AND METHODS FOR WOUND HEALING AND HAIR GROWTH USING POLYELECTROLYTE COMPLEX (PEC) FILMS
This disclosure provides methods for inhibiting glycerol kinase (GK) to treat or prevent a disease associated with elevated levels of serum triglycerides (TAGs) metabolic dysfunction- associated steatotic liver disease (MASLD). Also provided are novel nucleic acids capable of inhibiting GK.
This disclosure provides novel frameworks for subject identification or authentication. Compared, with conventional facial recognition methods, the disclosed frameworks can significantly cut the cost of calculating facial recognition. With such a lightweight design, the 5 disclosed frameworks are scalable and can be deployed on resource-constrained devices.
An analog neural network may include a convolutional layer including at least one convolutional processing unit (CvPU). Each CvPU can include: a center node capacitor, a set of neighbor node capacitors, a plurality of conductance elements between the center node capacitor and the set of neighbor node capacitors, and a plurality of analog adder circuits, wherein the center node capacitor and a neighbor node capacitor of the set of neighbor node capacitors are connected as inputs to an analog adder circuit of the plurality of analog adder circuits.
An intraoral scan alignment tool including a single-piece body, the body including a head having at least one alignment groove, a neck, and a projection extending from the neck. The projection is configured to be removably disposed into a bone of a jaw without a surgical incision, and the head is configured to be a stationary stop for aligning at least one scan of the jaw with another scan of the jaw.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
H04B 11/00 - Transmission systems employing ultrasonic, sonic or infrasonic waves
H04N 13/161 - Encoding, multiplexing or demultiplexing different image signal components
H04N 19/00 - Methods or arrangements for coding, decoding, compressing or decompressing digital video signals
H04N 19/40 - Methods or arrangements for coding, decoding, compressing or decompressing digital video signals using video transcoding, i.e. partial or full decoding of a coded input stream followed by re-encoding of the decoded output stream
H04N 19/44 - Decoders specially adapted therefor, e.g. video decoders which are asymmetric with respect to the encoder
H04B 13/02 - Transmission systems in which the medium consists of the earth or a large mass of water thereon, e.g. earth telegraphy
Described herein is a diagnostic catheter and a catheter system including the same. The diagnostic catheter of the disclosure is configured for advancing from a first blood vessel (such as a subclavian artery or descending aorta artery) into a second blood vessel (such as a patient head or neck artery) that forms a large angle with the first blood vessel at the bifurcation point of the two blood vessels. The diagnostic catheter of the disclosure includes an inflatable balloon coupled to or formed on an exterior surface of the distal region, which is able to anchor the distal portion of the diagnostic catheter near or just inside the second blood vessel, thereby simplifying the subsequent navigation steps. Also described herein are methods of using the diagnostic catheter and the catheter system to navigate in the blood vessel networks of patients.
This invention disclosure provides nucleic acids, reagents, and methods for profding cell receptor repertoires. The disclosed method is able to distinguish which immune receptor arrangements are present in single cells from amongst the millions of possible immune receptor arrangements. Furthermore, the method can report on the immune receptor arrangement that is present in each of 100,000 or more cells in a single assay, thus defining an individual's immune repertoire. Notably, the disclosed method is applicable for profiling repertoires of various receptors with somatic rearrangements, including that of T-cell receptors or B-cell receptors.
G01N 25/04 - Investigating or analysing materials by the use of thermal means by investigating changes of state or changes of phaseInvestigating or analysing materials by the use of thermal means by investigating sintering of melting pointInvestigating or analysing materials by the use of thermal means by investigating changes of state or changes of phaseInvestigating or analysing materials by the use of thermal means by investigating sintering of freezing pointInvestigating or analysing materials by the use of thermal means by investigating changes of state or changes of phaseInvestigating or analysing materials by the use of thermal means by investigating sintering of softening point
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
The invention provides dual-targeted inhibitors of bacterial RNA polymerase having the general structural formula (I): wherein a is a benzoxazino-rifamycin or a spiro-rifamycin: y is a moiety that binds to the bridge-helix N-terminus target of a bacterial RNA polymerase; and P is a bond, two bonds, or a linker. The invention also provides compositions comprising such compounds, methods of making such compounds, and methods of using said compounds. The invention has applications in control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, and antibacterial therapy.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61P 31/06 - Antibacterial agents for tuberculosis
Self-limiting electrospray compositions including a non-charge-dissipative component and/or a charge-dissipative component. Self-limiting electrospray composition including a plurality of charge-dissipative components and excluding a non-charge-dissipative component. Methods for forming layers of self-limiting thickness. Methods for determining a conductivity of a material. Methods for repairing a flaw in a layer on a surface of an object.
B05D 1/04 - Processes for applying liquids or other fluent materials performed by spraying involving the use of an electrostatic field
B05D 5/00 - Processes for applying liquids or other fluent materials to surfaces to obtain special surface effects, finishes or structures
B29C 64/188 - Processes of additive manufacturing involving additional operations performed on the added layers, e.g. smoothing, grinding or thickness control
A device for catheterization includes a catheter sheath support mounted to a catheterization device and holding a catheter sheath, a carriage supporting a guide needle, and a connector to removably engage the catheter sheath support to the carriage. The carriage translates along an axis of insertion of the guide needle independent of the catheter sheath support when disengaged from the connector. An actuator controls separation of the carriage from the catheter sheath support at a uniform velocity in response to disengagement of the connector. Translation and separation may be automated. In response to detection of the vessel wall puncture, the carriage automatically releases from the catheter sheath support and retracts along the axis of insertion at the uniform velocity relative to the catheter sheath support, and the catheter sheath automatically advances into the target vessel along the axis of insertion at the uniform velocity while the carriage retracts.
A61M 5/42 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
A61M 25/06 - Body-piercing guide needles or the like
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
79.
Compositions And Methods Targeting G12 Signaling For Bronchodilator Therapy
Provided herein are methods for inhibiting contraction and/or promoting relaxation of airway smooth muscle cells (e.g., human airway smooth muscle cells), comprising contacting the cells with a Gα12 or RhoA inhibitor. Also provided herein are methods for inhibiting and/or treating bronchoconstriction or promoting bronchodilation in a subject, for example, a subject with airway hyperresponsiveness and/or a disease associated with bronchoconstriction, such as asthma, chronic obstructive pulmonary disease, chronic bronchitis, bronchiectasis or cystic fibrosis, using a Gα12 or RhoA inhibitor, as well as pharmaceutical compositions comprising a Gα12 or RhoA inhibitor.
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/50 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase involving creatine phosphokinase
C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
80.
IONIC LIQUID SUBSTITUTED POLYSACCHARIDE COMPOUNDS AND METHODS OF USE THEREOF
222 and at least one additional gas with the compounds and/or compositions of the present disclosure and/or films, powders, or fibers comprising the same.
Methods for fabricating a polysilicon doped structure include forming a first multilayer structure by growth/deposition of an oxide layer on a first substrate and disposing amorphous silicon on the oxide layer. The methods further include forming a second multilayer structure by disposing a spin-on-dopant on a second substrate. The methods further include creating a stack by placing the second multilayer structure on the first multilayer structure so that the spin-on-dopant is near the amorphous silicon. And the methods include applying heat to the stack to cause the first multilayer structure to transform into the polysilicon doped structure.
H01L 21/20 - Deposition of semiconductor materials on a substrate, e.g. epitaxial growth
C23C 16/01 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes on temporary substrates, e.g. on substrates subsequently removed by etching
The invention provides a compound of formula I.
The invention provides a compound of formula I.
The invention provides a compound of formula I.
or a salt thereof, wherein R1—R2 have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as antiviral agents.
C07D 209/52 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 31/428 - Thiazoles condensed with carbocyclic rings
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
83.
COMPOSITIONS AND METHODS FOR TREATING DENTIN CARIES
The present disclosure provides for oral compositions and method of using the same for treating dentin using an orally acceptable salt which includes a divalent metal cation and an anionic counterion, such as an ascorbic acid phosphate counterion and a silane coupling agent. The methods provide for remineralization and reinforcing of dentin by doping with the divalent cation, thereby preventing and/or reducing the occurrence of dental caries
A robot is navigated to a target location passively collision-free. An obstacle (21) is detected by sensors. An obstacle velocity dynamic window is calculated within a control cycle. An obstacle mobility boundary is determined and inflated to an inflated boundary that includes a collision threshold. Admissible velocities of the robot are identified as those in which the robot would be outside the inflated boundary at a next control cycle or the robot velocity is reduced if there is no admissible velocity. An optimal velocity among admissible velocities is selected. The position of the robot is updated, and the process is repeated until the target location is reached. Without the use of an inflated boundary, admissible velocities of the robot are identified as those that avoid projected obstacle boundaries for a preset number of possible obstacle trajectories.
The Trustees of the University of Pennsylvania (USA)
Inventor
Xie, Pengfei
Javanmard, Mehdi
Allen, Mark George
Shen, Wen
Song, Naixin
Abstract
A sensor for detecting a target analyte in a sample includes a pair of conducting electrodes that are separated by a gap. An insulator is disposed in the gap between the electrodes. Plural wells are defined by one of the electrodes and the insulator, to expose the other of the electrodes. The wells are configured to receive a sample including a target analyte. The target analyte, when present in the sample received in the wells, modulates an impedance between the electrodes. The modulated impedance, which is measurable with an applied electrical voltage, is indicative of the concentration of the target analyte in the sample. The wells can include antibodies immobilized inside the wells, to bind the target analyte, which can be a cytokine. Also provided are a method for label-free sensing of a target analyte in a sample, and a transcutaneous impedance sensor for label-free, in-situ biomarker detection.
Various embodiments comprise systems, methods, architectures, mechanisms and apparatus providing secure physical layer (PHY) transmission via metamaterial (MTM) leaky-wave antennas (LWAs) using directed modulation (DM) transmitters such as for orthogonal frequency-division multiplexing (OFDM) and non-contiguous (NC) OFDM transmissions, where the DM functionalities exploit the property of time-modulated arrays (TMAs) realized in 1-D and 2-D spaces through the MTM-LWAs.
H01Q 13/28 - Non-resonant leaky-waveguide or transmission-line antennas Equivalent structures causing radiation along the transmission path of a guided wave comprising elements constituting electric discontinuities and spaced in direction of wave propagation, e.g. dielectric elements or conductive elements forming artificial dielectric
H01Q 1/38 - Structural form of radiating elements, e.g. cone, spiral, umbrella formed by a conductive layer on an insulating support
H01Q 3/26 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the relative phase or relative amplitude of energisation between two or more active radiating elementsArrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the distribution of energy across a radiating aperture
87.
LOW PROFILE TRANSFER MECHANISM FOR CONTROLLED ENVIRONMENT
A system for transferring objects into a device inside a controlled environment includes a winch, tool and carousel. The winch includes a drum, and wire arrangement configured to be reversibly wound onto the drum by a first drive. The tool is suspended below a distal end of the wire arrangement and configured to suspend an object. Both the tool and the object are sized to fit inside a device located below the winch. The carousel is connected to a second drive configured to rotate the carousel around a vertical axis, and includes a storage space centered at a first horizontal angle and a pass-through opening at a different second horizontal angle. The pass-through opening being large enough to pass the tool and the object as the wire arrangement is unwound from the drum thereby lowering the tool and object inside the device.
B66C 1/24 - Single members engaging the loads from one side only
B66D 1/26 - Rope, cable, or chain winding mechanismsCapstans having several drums or barrels
F16M 13/02 - Other supports for positioning apparatus or articlesMeans for steadying hand-held apparatus or articles for supporting on, or attaching to, an object, e.g. tree, gate, window-frame, cycle
88.
METHODS AND COMPOSITIONS FOR THE BIOSYNTHESIS AND USE OF DEMETHYLATED POLYMETHOXY FLAVONES
A novel yeast strain and methods of use thereof for robust biosynthesis of demethylated polymethoxy flavones are disclosed. Also provided are method of administering demethylated polymethoxy flavones for the treatment of obesity and inflammatory a disease.
Various embodiments comprise systems, methods, architectures, mechanisms and apparatus for optical, radio frequency (RF), and/or acoustic data transmission by dividing each of one or more sequences of channel coded bits d into N blocks thereof, which are respectively spatially modulated (SM) with respective pilot sequences and mapped to constellations to provide thereby respective symbol streams, which are modulated in accordance with orthogonal signal division multiplexing (OSDM) to provide respective SM-OSDM signals, which are transmitted via optical sources, RF antennae, acoustic transducers, and the like during respective timeslots such that a receiver associated with a plurality of receiving devices may reconstruct the bitstream used to form the one or more sequences of channel coded bits d.
H04B 10/80 - Optical aspects relating to the use of optical transmission for specific applications, not provided for in groups , e.g. optical power feeding or optical transmission through water
90.
DETECTION OF MULTIDRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS USING SUPERSELECTIVE PRIMER-BASED REAL-TIME PCR ASSAYS
This disclosure relates to assays and reagents for the detection of drug-resistance mutations in Mycobacterium. tuberculosis or of multidrug-resistant Mycobacterium tuberculosis.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
A hydroponic system for cultivation and harvesting of floating aquatic plants is provided. The hydroponic system includes an arrangement of a plurality of vertically-stacked cultivation trays, each tray containing an amount of fluent media on which floating aquatic plants are able to grow. The hydroponic system also includes a media reservoir in which fluent media is contained and subject to treatment before being circulated to the cultivation trays and a harvesting reservoir for receiving aquatic plants grown in the cultivation trays and harvested from the same. The hydroponic system further includes an automated control system that manages media flow into and from the trays and aquatic plant harvesting from the trays. A method of cultivating and harvesting floating aquatic plants is also provided.
B01J 3/06 - Processes using ultra-high pressure, e.g. for the formation of diamondsApparatus therefor, e.g. moulds or dies
B30B 11/00 - Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses or tabletting presses
fbp1Δfbp1Δ) mutant fungal cells and adjuvant ODN 2395. The pharmaceutical compositions can be administered by intranasal (IN) inhalation, subcutaneous (SC) injection, or intramuscular (IM) injection. Vaccination with a pharmaceutical composition confers host immunity to fungal infection in different host backgrounds and in different aged hosts.
The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase. In addition, administration of a matriptase antibody or immunoconjugates of a matriptase antibody and a cytotoxic agent in combination with administration of an immunomodulatory agent, such as thalidomide or an analog thereof, provides a more effective treatment of these cancers.
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
95.
CELLULARIZED NERVE REGENERATION GRAFT AND METHODS OF MAKING THE SAME
A cellularized nerve regeneration graft is disclosed that includes an electrospun biodegradable polymer conduit having an exterior surface and an interior luminal space, a plurality of fibroblasts seeded to the exterior surface of the conduit, and a system filling the interior luminal space of the conduit. The system may include a hydrogel matrix or augmented hydrogel matrix and Schwann cells. The cellularized nerve regeneration graft may be used in the repair of peripheral nerve injuries. Methods of making the cellularized nerve regeneration graft are also disclosed.
The present invention relates to novel primers and sloppy molecular beacon and molecular beacon probes for amplifying segments from different genes in Mycobacterium tuberculosis for identifying the presence of M.tb DNA and/or resistance to anti-tuberculosis drugs.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
This disclosure provides a microfluidic system (e.g., microfluidic cartridge, microfluidic chip) comprising two or more microfluidic flow channels for impedance-based detection of a biological entity in a sample. The disclosed system enables simultaneous measurements of a sample in two or more microfluidic flow channels to minimize faulty results. It eliminates the need of lysing samples and measuring them multiple times that is more time-consuming, and could introduce some variations across samples and devices.
G01N 15/12 - Investigating individual particles by measuring electrical or magnetic effects by observing changes in resistance or impedance across apertures when traversed by individual particles, e.g. by using the Coulter principle
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
Embodiments include methods, systems, and computer program products for detecting probe microparticle(s). One such embodiment applies an electric field to a biological entity. The electric field includes multiple frequencies. One or more of the multiple frequencies correspond to respective types of probe microparticles. Each type of probe microparticle includes a core and at least a partial metal oxide coating. Further, each type of probe microparticle is configured to produce a response corresponding to a respective frequency and conjugate to a corresponding type of biological entity. Responsive to applying the electric field, a response signal is measured. Then, based on the measured response signal, a presence or absence of probe microparticle(s) conjugated to the biological entity is detected.
G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
G01N 15/1409 - Handling samples, e.g. injecting samples
The present disclosure relates to gene editing, related systems, and uses thereof. The gene editing is mediated by reverse transcription of a modular RNA template anchored by a complementary sequence within a modified guide RNA.
A high efficiency microfluidic biobarrier platform, system, and method permit an in vitro examination of a biobarrier under physiological flow conditions. The platform comprises an inlet, a first member, and an outlet. The inlet receives an influx of fluid. The first member retains the biobarrier, and the member includes a channel in fluid communication with the inlet to receive the fluid and to pass the fluid adjacent to the biobarrier. The outlet directs an outflux of the fluid. The microfluidic platform features built-in plastic electrodes to assess changes in biobarrier impedance in real-time. A system includes the platform, a pump to provide the fluid, a media collecting reservoir to receive the fluid from the platform, and an impedance analyzer to measure changes in biobarrier impedance. A method uses the platform in the system to determine the integrity of the biobarrier and its permeability across the cell barrier.
